albuterol has been researched along with Cystic Fibrosis in 79 studies
Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Cystic Fibrosis: An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effectiveness of maintenance albuterol aerosol therapy in cystic fibrosis (CF) was assessed by comparing spirometric measurements at the beginning and end of 1 year." | 9.08 | Short-term and long-term effects of albuterol aerosol therapy in cystic fibrosis: a preliminary report. ( Barbero, GJ; Gayer, D; König, P; Shaffer, J, 1995) |
| "Twenty-four hospitalized patients with cystic fibrosis were enrolled into a 2-d, double-blind, placebo-controlled, randomized crossover trial comparing albuterol inhalation aerosol with a saline placebo." | 9.08 | The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. ( Colombo, JL; Hordvik, NL; Judy, CG; Sammut, PH; Strizek, SJ, 1996) |
| "Data regarding the role of inhaled colistin in critically ill pediatric patients without cystic fibrosis are scarce." | 7.76 | Inhaled colistin for the treatment of tracheobronchitis and pneumonia in critically ill children without cystic fibrosis. ( Falagas, ME; Kafetzis, DA; Korbila, IP; Papadatos, JH; Sideri, G; Vouloumanou, EK, 2010) |
| "To evaluate whether respiratory therapy followed by the use of inhaled albuterol modifies the pulmonary deposition of inhaled tobramycin in patients with cystic fibrosis (CF) and whether pulmonary deposition correlates with disease severity or genotype." | 7.75 | Pulmonary deposition of inhaled tobramycin prior to and after respiratory therapy and use of inhaled albuterol in cystic fibrosis patients colonized with Pseudomonas aeruginosa. ( Etchebere, EC; Grotta, MB; Ribeiro, AF; Ribeiro, JD; Ribeiro, MA; Romanato, J, 2009) |
| "Multiple aspects of lung function were measured in 17 cystic fibrosis (CF) patients on four occasions: without therapy (0); with oral theophylline medication (Th); after inhalation of salbutamol (beta 2); and with combined medication (Th + beta 2)." | 7.67 | Airway obstruction and airway wall instability in cystic fibrosis: the isolated and combined effect of theophylline and sympathomimetics. ( Eber, E; Oberwaldner, B; Zach, MS, 1988) |
| "The effectiveness of maintenance albuterol aerosol therapy in cystic fibrosis (CF) was assessed by comparing spirometric measurements at the beginning and end of 1 year." | 5.08 | Short-term and long-term effects of albuterol aerosol therapy in cystic fibrosis: a preliminary report. ( Barbero, GJ; Gayer, D; König, P; Shaffer, J, 1995) |
| "Twenty-four hospitalized patients with cystic fibrosis were enrolled into a 2-d, double-blind, placebo-controlled, randomized crossover trial comparing albuterol inhalation aerosol with a saline placebo." | 5.08 | The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. ( Colombo, JL; Hordvik, NL; Judy, CG; Sammut, PH; Strizek, SJ, 1996) |
| "Nebulized ticarcillin can cause bronchoconstriction in children with cystic fibrosis (CF)." | 5.07 | Comparison of efficacy of salbutamol and sodium cromoglycate in the prevention of ticarcillin-induced bronchoconstriction. ( Chua, HL; LeSouëf, PN; Sly, PD; Walker, SL, 1993) |
| "Patients with cystic fibrosis had a better acute bronchodilator response to albuterol and ipratropium bromide than to either drug alone." | 5.07 | Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis. ( Chernick, V; Holbrow, J; Sanchez, I, 1992) |
| "Data regarding the role of inhaled colistin in critically ill pediatric patients without cystic fibrosis are scarce." | 3.76 | Inhaled colistin for the treatment of tracheobronchitis and pneumonia in critically ill children without cystic fibrosis. ( Falagas, ME; Kafetzis, DA; Korbila, IP; Papadatos, JH; Sideri, G; Vouloumanou, EK, 2010) |
| "To evaluate whether respiratory therapy followed by the use of inhaled albuterol modifies the pulmonary deposition of inhaled tobramycin in patients with cystic fibrosis (CF) and whether pulmonary deposition correlates with disease severity or genotype." | 3.75 | Pulmonary deposition of inhaled tobramycin prior to and after respiratory therapy and use of inhaled albuterol in cystic fibrosis patients colonized with Pseudomonas aeruginosa. ( Etchebere, EC; Grotta, MB; Ribeiro, AF; Ribeiro, JD; Ribeiro, MA; Romanato, J, 2009) |
| "The purpose of this study is to determine hyperpolarized helium 3 (HHe) magnetic resonance (MR) findings of the lung in patients with cystic fibrosis (CF) compared with healthy subjects and determine whether HHe MR can detect changes after bronchodilator therapy or mechanical airway mucus clearance treatment." | 3.73 | Hyperpolarized HHe 3 MRI of the lung in cystic fibrosis: assessment at baseline and after bronchodilator and airway clearance treatment. ( Altes, TA; Brookeman, JR; de Lange, EE; Froh, DK; Mentore, K; Paget-Brown, AO, 2005) |
| "Bicycle ergospirometry was performed on 14 patients with cystic fibrosis (CF), for evaluating the effects of salbutamol and theophylline on the ventilatory response to exercise." | 3.68 | Increased physiological dead space during exercise after bronchodilation in cystic fibrosis. ( Friedrichs, F; Heimann, G; Kusenbach, G; Skopnik, H, 1993) |
| "Multiple aspects of lung function were measured in 17 cystic fibrosis (CF) patients on four occasions: without therapy (0); with oral theophylline medication (Th); after inhalation of salbutamol (beta 2); and with combined medication (Th + beta 2)." | 3.67 | Airway obstruction and airway wall instability in cystic fibrosis: the isolated and combined effect of theophylline and sympathomimetics. ( Eber, E; Oberwaldner, B; Zach, MS, 1988) |
| "Acute administration of 3% and 7% HS appears to be safe and well-tolerated in most young children with CF." | 2.73 | Safety and tolerability of inhaled hypertonic saline in young children with cystic fibrosis. ( Davis, SD; Dellon, EP; Donaldson, SH; Johnson, R, 2008) |
| " There is a need for long-term randomised controlled trials of these technologies to determine patient-focused outcomes (such as quality of life and burden of care), safe and effective dosing levels of medications and clinical outcomes (such as hospitalisations and need for antibiotics) and an economic evaluation of their use." | 2.49 | Nebuliser systems for drug delivery in cystic fibrosis. ( Daniels, T; Mills, N; Whitaker, P, 2013) |
| "Albuterol concentration was measured with spectrophotometry at 276 nm." | 1.48 | Crossover Evaluation of Compressors and Nebulizers Typically Used by Cystic Fibrosis Patients. ( Awad, SM; Berlinski, A, 2018) |
| "Albuterol was assayed via spectrophotometry." | 1.40 | In vitro evaluation of positive expiratory pressure devices attached to nebulizers. ( Berlinski, A, 2014) |
| "These results suggest that there are differences in lung diffusion and peripheral SaO(2) according to genetic variation of the ADRB2 at position 27 which could play a potential role in dosing options or adjustments that may be required according to genotype." | 1.37 | Influence of genetic variation of the β2-adrenergic receptor on lung diffusion in patients with cystic fibrosis. ( Daines, CL; Foxx-Lupo, WT; Morgan, WJ; Patanwala, AE; Phan, H; Skrentny, TT; Snyder, EM; Sprissler, R; Traylor, BR; Wheatley, CM, 2011) |
| "Cystic fibrosis is an autosomal recessive disease affecting approximately 1 in 2500 live births." | 1.34 | Calculating expected lung deposition of aerosolized administration of AAV vector in human clinical studies. ( Anklesaria, P; Coates, AL; Dutzar, B; Leung, K; Louca, E; Munson, K, 2007) |
| "The use of inhaled antibiotics in the treatment of cystic fibrosis has become widespread despite controversy in the literature as to the appropriate dosing regimen and its effectiveness." | 1.30 | The choice of jet nebulizer, nebulizing flow, and addition of albuterol affects the output of tobramycin aerosols. ( Coates, AL; Kelemen, S; MacDonald, J; MacNeish, CF; Meisner, D; Thibert, R; Vadas, E, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (13.92) | 18.7374 |
| 1990's | 27 (34.18) | 18.2507 |
| 2000's | 19 (24.05) | 29.6817 |
| 2010's | 20 (25.32) | 24.3611 |
| 2020's | 2 (2.53) | 2.80 |
| Authors | Studies |
|---|---|
| Escher, A | 1 |
| Kieninger, E | 1 |
| Groof, S | 1 |
| Savas, ST | 1 |
| Schneiter, M | 1 |
| Tschanz, SA | 1 |
| Frenz, M | 1 |
| Latzin, P | 1 |
| Casaulta, C | 1 |
| Müller, L | 1 |
| Kramer, EL | 2 |
| Madala, SK | 1 |
| Hudock, KM | 1 |
| Davidson, C | 1 |
| Clancy, JP | 2 |
| Nenna, R | 1 |
| Midulla, F | 1 |
| Lambiase, C | 1 |
| De Castro, G | 1 |
| Zicari, AM | 1 |
| Indinnimeo, L | 1 |
| Cimino, G | 1 |
| Troiani, P | 1 |
| Quattrucci, S | 1 |
| Tancredi, G | 1 |
| Awad, SM | 1 |
| Berlinski, A | 3 |
| Brewington, JJ | 1 |
| Backstrom, J | 1 |
| Feldman, A | 1 |
| Moncivaiz, JD | 1 |
| Ostmann, AJ | 1 |
| Zhu, X | 1 |
| Lu, LJ | 1 |
| Daniels, T | 1 |
| Mills, N | 1 |
| Whitaker, P | 1 |
| Blau, H | 1 |
| Linnane, B | 1 |
| Carzino, R | 1 |
| Tannenbaum, EL | 1 |
| Skoric, B | 1 |
| Robinson, PJ | 1 |
| Robertson, C | 1 |
| Ranganathan, SC | 1 |
| Awad, S | 1 |
| Williams, DK | 1 |
| Trotta, T | 1 |
| Guerra, L | 1 |
| Piro, D | 1 |
| d'Apolito, M | 1 |
| Piccoli, C | 1 |
| Porro, C | 1 |
| Giardino, I | 1 |
| Lepore, S | 1 |
| Castellani, S | 1 |
| Di Gioia, S | 1 |
| Petrella, A | 1 |
| Maffione, AB | 1 |
| Casavola, V | 1 |
| Capitanio, N | 1 |
| Conese, M | 1 |
| Wheatley, CM | 4 |
| Baker, SE | 3 |
| Morgan, MA | 2 |
| Martinez, MG | 2 |
| Morgan, WJ | 4 |
| Wong, EC | 2 |
| Karpen, SR | 3 |
| Snyder, EM | 4 |
| Liu, B | 1 |
| Rowe, SM | 1 |
| Van Iterson, EH | 1 |
| Halfhide, C | 2 |
| Evans, HJ | 2 |
| Couriel, J | 2 |
| Stringer, E | 1 |
| Cossaboon, C | 1 |
| Han, S | 1 |
| Taylor-Cousar, JL | 1 |
| Weckmann, M | 1 |
| Schultheiss, C | 1 |
| Hollaender, A | 1 |
| Bobis, I | 1 |
| Rupp, J | 1 |
| Kopp, MV | 1 |
| Vijftigschild, LA | 1 |
| Berkers, G | 1 |
| Dekkers, JF | 1 |
| Zomer-van Ommen, DD | 1 |
| Matthes, E | 1 |
| Kruisselbrink, E | 1 |
| Vonk, A | 1 |
| Hensen, CE | 1 |
| Heida-Michel, S | 1 |
| Geerdink, M | 1 |
| Janssens, HM | 1 |
| van de Graaf, EA | 1 |
| Bronsveld, I | 1 |
| de Winter-de Groot, KM | 1 |
| Majoor, CJ | 1 |
| Heijerman, HG | 1 |
| de Jonge, HR | 1 |
| Hanrahan, JW | 1 |
| van der Ent, CK | 1 |
| Beekman, JM | 1 |
| Dellon, EP | 1 |
| Donaldson, SH | 1 |
| Johnson, R | 1 |
| Davis, SD | 1 |
| Delavoie, F | 1 |
| Molinari, M | 1 |
| Milliot, M | 1 |
| Zahm, JM | 1 |
| Coraux, C | 1 |
| Michel, J | 1 |
| Balossier, G | 1 |
| Grotta, MB | 1 |
| Etchebere, EC | 1 |
| Ribeiro, AF | 1 |
| Romanato, J | 1 |
| Ribeiro, MA | 1 |
| Ribeiro, JD | 1 |
| Collawn, JF | 1 |
| Bebok, Z | 1 |
| Matalon, S | 1 |
| Bossard, F | 1 |
| Silantieff, E | 1 |
| Lavazais-Blancou, E | 1 |
| Robay, A | 1 |
| Sagan, C | 1 |
| Rozec, B | 1 |
| Gauthier, C | 1 |
| Falagas, ME | 1 |
| Sideri, G | 1 |
| Korbila, IP | 1 |
| Vouloumanou, EK | 1 |
| Papadatos, JH | 1 |
| Kafetzis, DA | 1 |
| O'Connell, OJ | 1 |
| O'Farrell, C | 1 |
| Harrison, MJ | 1 |
| Eustace, JA | 1 |
| Henry, MT | 1 |
| Plant, BJ | 1 |
| O'Malley, CA | 1 |
| Traylor, BR | 1 |
| Skrentny, TT | 1 |
| Foxx-Lupo, WT | 1 |
| Phan, H | 1 |
| Patanwala, AE | 1 |
| Daines, CL | 1 |
| Sprissler, R | 1 |
| Salvatore, D | 1 |
| D'Andria, M | 1 |
| Hordvik, NL | 3 |
| Sammut, PH | 3 |
| Judy, CG | 3 |
| Colombo, JL | 3 |
| Marks, JH | 1 |
| Hare, KL | 1 |
| Saunders, RA | 1 |
| Homnick, DN | 3 |
| König, P | 3 |
| Goldstein, D | 2 |
| Poehlmann, M | 1 |
| Rife, D | 1 |
| Ge, B | 1 |
| Hewett, J | 1 |
| Dodd, JD | 1 |
| Barry, SC | 1 |
| Daly, LE | 1 |
| Gallagher, CG | 1 |
| Mentore, K | 1 |
| Froh, DK | 1 |
| de Lange, EE | 1 |
| Brookeman, JR | 1 |
| Paget-Brown, AO | 1 |
| Altes, TA | 1 |
| Elkins, MR | 1 |
| Robinson, M | 1 |
| Rose, BR | 1 |
| Harbour, C | 1 |
| Moriarty, CP | 1 |
| Marks, GB | 1 |
| Belousova, EG | 1 |
| Xuan, W | 1 |
| Bye, PT | 1 |
| Kamin, W | 1 |
| Schwabe, A | 1 |
| Krämer, I | 1 |
| Davies, PL | 1 |
| Doull, IJ | 1 |
| Child, F | 1 |
| Leung, K | 1 |
| Louca, E | 1 |
| Munson, K | 1 |
| Dutzar, B | 1 |
| Anklesaria, P | 1 |
| Coates, AL | 3 |
| Serisier, DJ | 1 |
| Coates, AD | 1 |
| Bowler, SD | 1 |
| Shamsuddin, AK | 1 |
| Reddy, MM | 1 |
| Quinton, PM | 1 |
| Kattan, M | 1 |
| Mansell, A | 1 |
| Levison, H | 1 |
| Corey, M | 1 |
| Krastins, IR | 1 |
| Svenonius, E | 1 |
| Arborelius, M | 1 |
| Kautto, R | 1 |
| Kornfält, R | 1 |
| Lindberg, T | 1 |
| Ormerod, LP | 1 |
| Thomson, RA | 1 |
| Anderson, CM | 1 |
| Stableforth, DE | 1 |
| White, F | 1 |
| de Castro, C | 1 |
| Peckham, DG | 1 |
| Conn, A | 1 |
| Chotai, C | 1 |
| Lewis, S | 1 |
| Knox, AJ | 1 |
| Sanchez, I | 5 |
| Desmond, KJ | 1 |
| Demizio, DL | 1 |
| Allen, PD | 1 |
| MacDonald, ND | 1 |
| Natale, JE | 1 |
| Pfeifle, J | 1 |
| Chua, HL | 1 |
| Walker, SL | 1 |
| LeSouëf, PN | 1 |
| Sly, PD | 1 |
| Kusenbach, G | 1 |
| Friedrichs, F | 1 |
| Skopnik, H | 1 |
| Heimann, G | 1 |
| De Koster, J | 1 |
| Holbrow, J | 2 |
| Chernick, V | 4 |
| Koller, DY | 1 |
| Herouy, Y | 1 |
| Götz, M | 1 |
| Hagel, E | 1 |
| Urbanek, R | 1 |
| Eichler, I | 1 |
| Demnati, R | 1 |
| Michoud, MC | 1 |
| Jeanneret-Grosjean, A | 1 |
| Ong, H | 1 |
| Du Souich, P | 1 |
| Gayer, D | 1 |
| Barbero, GJ | 2 |
| Shaffer, J | 1 |
| Strizek, SJ | 1 |
| Kelley, TJ | 1 |
| Al-Nakkash, L | 1 |
| Cotton, CU | 1 |
| Drumm, ML | 1 |
| MacNeish, CF | 1 |
| Meisner, D | 1 |
| Kelemen, S | 1 |
| Thibert, R | 1 |
| MacDonald, J | 1 |
| Vadas, E | 1 |
| Bargon, J | 1 |
| Viel, K | 1 |
| Dauletbaev, N | 1 |
| Wiewrodt, R | 1 |
| Buhl, R | 1 |
| Devadason, SG | 1 |
| Everard, ML | 1 |
| Linto, JM | 1 |
| Le Souëf, PN | 1 |
| Hellinckx, J | 1 |
| De Boeck, K | 1 |
| Demedts, M | 1 |
| Poehler, J | 1 |
| Brand, PL | 1 |
| Ziebach, R | 1 |
| Pietsch-Breitfeld, B | 1 |
| Bichler, M | 1 |
| Busch, A | 1 |
| Riethmüller, J | 1 |
| Stern, M | 1 |
| Mearns, MB | 1 |
| Powell, RE | 1 |
| Merkus, PJ | 1 |
| Verver, S | 1 |
| van Essen-Zandvliet, EE | 1 |
| Duiverman, EJ | 1 |
| Kerrebijn, KF | 1 |
| Quanjer, PH | 1 |
| Avital, A | 1 |
| Kraemer, R | 4 |
| Birrer, P | 2 |
| Modelska, K | 1 |
| Aebischer, CC | 1 |
| Schöni, MH | 3 |
| Eggleston, PA | 1 |
| Rosenstein, BJ | 1 |
| Stackhouse, CM | 1 |
| Mellits, ED | 1 |
| Baumgardner, RA | 1 |
| Lutchen, KR | 1 |
| Habib, RH | 1 |
| Dorkin, HL | 1 |
| Wall, MA | 1 |
| Maayan, C | 2 |
| Bar-Yishay, E | 2 |
| Yaacobi, T | 1 |
| Marcus, Y | 1 |
| Katznelson, D | 1 |
| Yahav, Y | 1 |
| Godfrey, S | 2 |
| Eber, E | 1 |
| Oberwaldner, B | 1 |
| Zach, MS | 1 |
| Vaisman, N | 2 |
| Levy, LD | 1 |
| Pencharz, PB | 1 |
| Tan, YK | 2 |
| Soldin, SJ | 1 |
| Canny, GJ | 2 |
| Hahn, E | 1 |
| Koren, G | 1 |
| Soldin, S | 1 |
| Pencharz, P | 1 |
| Beardsmore, CS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Nebulised 5% Hypertonic Saline in Children With Chronic Suppurative Lung Disease[NCT04765033] | Phase 4 | 46 participants (Actual) | Interventional | 2021-02-04 | Completed | ||
| Modifying Genes in Cystic Fibrosis: The Beta-2 Adrenergic Receptors and Epithelial Na+ Channels[NCT01880723] | 32 participants (Actual) | Interventional | 2009-05-31 | Completed | |||
| Randomized Cross Over Study of Inhaled Hypertonic Xylitol Versus Hypertonic Saline in Stable Subjects With Cystic Fibrosis[NCT01355796] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| Symptom Based Performance of Airway Clearance Therapy After Starting Highly Effective CFTR Modulator Therapy for Cystic Fibrosis[NCT05392855] | 30 participants (Anticipated) | Interventional | 2023-09-05 | Recruiting | |||
| A Chart Review Assessing the Effects of Nebulised Hypertonic Saline on Respiratory-related Complications in Children and Young People With Neuromuscular Disease and Cerebral Palsy[NCT03623698] | 24 participants (Actual) | Observational | 2018-06-15 | Completed | |||
| The Effects of Long Term Inhalation of Hypertonic Saline in Subjects With Cystic Fibrosis[NCT00271310] | Phase 3 | 164 participants | Interventional | 2000-09-30 | Completed | ||
| The Long Term Effect of Inhaled Hypertonic Saline (6%) in Patients With Non-cystic Fibrosis Bronchiectasis.[NCT00484263] | Phase 3 | 40 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| Sustained Impact of Hypertonic Saline on Mucociliary Clearance in Young Children With Cystic Fibrosis[NCT01031706] | 23 participants (Actual) | Interventional | 2009-09-30 | Completed | |||
| Nebulized Hypertonic Saline for Mechanically Ventilated Children[NCT01945944] | Phase 1/Phase 2 | 18 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| Pragmatic Implementation Trial of a CF Primary Palliative Care Intervention[NCT04923880] | 643 participants (Actual) | Interventional | 2021-06-25 | Active, not recruiting | |||
| Durability of Hypertonic Saline for Enhancing Mucociliary Clearance in Cystic Fibrosis[NCT01094704] | Phase 1 | 16 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Investigating the Role of Nebulised Mucolytic Therapy During Lower Respiratory Tract Infections Post Lung Transplantation.[NCT01952470] | Phase 2 | 32 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| Comparison of Breath-Enhanced and T-Piece Nebulizers in Children With Acute Asthma[NCT02566902] | 118 participants (Actual) | Interventional | 2015-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Using the rebreathe technique the diffusion capacity of the lungs for carbon monoxide and nitric oxide were measured, and this allowed for the determination of alveolar-capillary membrane conductance and pulmonary capillary blood volume. These measurements were made at baseline and 30-, 60- and 90-minutes post albuterol administration in cystic fibrosis and healthy subjects. (NCT01880723)
Timeframe: baseline, 30-, 60- and 90-minutes post albuterol administration
| Intervention | mL/min/mmHg (Mean) | |||
|---|---|---|---|---|
| Baseline | 30 minutes post | 60 minutes post | 90 minutes post | |
| Cystic Fibrosis | 17.3 | 17.4 | 17.0 | 17.1 |
| Healthy | 21.5 | 21.6 | 21.6 | 21.2 |
Using the rebreathe technique the diffusion capacity of the lungs for carbon monoxide and nitric oxide were measured, and this allowed for the determination of alveolar-capillary membrane conductance and pulmonary capillary blood volume. These measurements were made at baseline and 30-, 60- and 90-minutes post albuterol administration in cystic fibrosis and healthy subjects. (NCT01880723)
Timeframe: baseline, 30-, 60- and 90-minutes post albuterol administration
| Intervention | mL/min/mmHg (Mean) | |||
|---|---|---|---|---|
| Baseline | 30 minutes post | 60 minutes post | 90 minutes post | |
| Cystic Fibrosis | 55.0 | 56.4 | 56.2 | 58.5 |
| Healthy | 70.3 | 70.8 | 72.1 | 73.0 |
We collected exhaled breath condensate (EBC) samples, with subjects breathing on a Jaeger EcoScreen for 20 minutes. EBC samples were collected in cystic fibrosis and healthy subjects before and 30-, 60-, and 90-minutes following albuterol administration. (NCT01880723)
Timeframe: up to 90-minutes post albuterol
| Intervention | mmol/L (Mean) | |||
|---|---|---|---|---|
| Baseline | 30 minutes post | 60 minutes post | 90 minutes post | |
| Cystic Fibrosis | 2.24 | 2.11 | 1.73 | 1.86 |
| Healthy | 2.58 | 1.97 | 2.37 | 2.23 |
"The calculation of net chloride efflux was used to account for the paracellular reabsorption of Cl- that will follow the reabsorption of Na+ to maintain electroneutral ion flux. Thus, the net chloride efflux calculation used was the gross chloride concentration plus the absolute value of the percent change in sodium from baseline multiplied by the gross chloride concentration for each time point:~Net Cl- efflux - [Cl- X-min post] + (([Na+ X-min post]-[Na+Baseline])/ [Na+Baseline]) x [Cl- X-min post])" (NCT01880723)
Timeframe: baseline to 90 minutes post albuterol administration
| Intervention | mmol/L (Mean) | |||
|---|---|---|---|---|
| Baseline | 30 minutes post | 60 minutes post | 90 minutes post | |
| Cystic Fibrosis | 0.037 | 0.048 | 0.057 | 0.050 |
| Healthy | 0.064 | 0.078 | 0.084 | 0.077 |
A finger pulse oximeter allowed for the measurement of peripheral oxygen saturation at baseline, 30-, 60- and 90-minutes post albuterol in cystic fibrosis and healthy subjects. (NCT01880723)
Timeframe: baseline, 30-, 60- and 90-minutes post albuterol
| Intervention | percent of oxygenated hemoglobin (Mean) | |||
|---|---|---|---|---|
| Baseline | 30 minutes post | 60 minutes post | 90 minutes post | |
| Cystic Fibrosis | 98 | 98 | 98 | 99 |
| Healthy | 99 | 100 | 99 | 99 |
Change from baseline in FEV1(maximal amount of air you can forcefully exhale in one second) % predicted (NCT01355796)
Timeframe: Baseline and 14 days
| Intervention | percentage of predicted (Mean) |
|---|---|
| Xylitol | -0.1 |
| Saline | 1.4 |
Difference from baseline in density of Pseudomonas aeruginosa colonization per gram of sputum, (NCT01355796)
Timeframe: baseline and 14 days
| Intervention | Log colony forming units (Mean) |
|---|---|
| Xylitol | -1.98 |
| Saline | 0.93 |
Nocturnal oxygen saturation (NCT03623698)
Timeframe: Change from baseline (before treatment) and 12 months after treatment
| Intervention | percentage of SpO2 (Mean) |
|---|---|
| Before Treatment | 96.55 |
| After Treatment | 96.53 |
Nocturnal Apnoea Hipopnea index: total number of apnea events plus hypopnea events divided by the total number of minutes of actual sleep time and then multiplied by 60. (NCT03623698)
Timeframe: Change from baseline (before treatment) and 12 months after treatment
| Intervention | Events per hour of sleep (Mean) |
|---|---|
| Before Treatment | 8.53 |
| After Treatment | 1.38 |
The number of apneas recorded during the study per hour of sleep (NCT03623698)
Timeframe: Change from baseline (before treatment) and 12 months after treatment
| Intervention | Events per hour of sleep (Mean) |
|---|---|
| Before Treatment | 4.87 |
| After Treatment | 0.40 |
Rate of decline per year of Tiffenau index (NCT03623698)
Timeframe: Change from baseline (before treatment) and 12 months after treatment
| Intervention | percentage of predicted (Median) |
|---|---|
| Before Treatment | 97.37 |
| After Treatment | 98.89 |
"Rate of decline of Forced Expiratory Volume in first second (FEV1) percentage of predicted.~Rate of decline is a measure of slope of FEV1 percentage predicted.~Baseline slope: [(FEV1% at baseline / FEV1% 12 months before treatment) - 1] * 100 After treatment slope: [(FEV1% 12 months after treatment / FEV1% at baseline) - 1] * 100" (NCT03623698)
Timeframe: Change from the baseline (before treatment) and 12 months after treatment
| Intervention | percentage of predicted (Median) |
|---|---|
| Before Treatment | -8.03 |
| After Treatment | 4.00 |
"Rate of decline of Forced Vital Capacity (FVC) percentage of predicted. Rate of decline is a measure of slope of FVC%.~Baseline slope: [(FVC% at baseline / FVC% 12 months before treatment) - 1] * 100 After treatment slope: [(FVC% 12 months after treatment / FVC% at baseline) - 1] * 100" (NCT03623698)
Timeframe: Change from baseline (before treatment) and 12 months after treatment
| Intervention | percentage of predicted (Median) |
|---|---|
| Before Treatment | -7.44 |
| After Treatment | 7.00 |
Oxygen desaturation index: Number of desaturations per hour of sleep (NCT03623698)
Timeframe: Change from baseline (before treatment) and 12 months after treatment
| Intervention | Events per hour of sleep (Mean) |
|---|---|
| Before Treatment | 4.26 |
| After Treatment | 3.32 |
Number of respiratory exacerbations that required not planned hospitalisation (NCT03623698)
Timeframe: Change from baseline (before treatment) and 12 months after treatment
| Intervention | Hospitalisations (Median) |
|---|---|
| Before Treatment | 1 |
| After Treatment | 0 |
Peak expiratory flow percentage of predicted (NCT03623698)
Timeframe: Change from baseline peak expiratory flow at 12 months after starting treatment with hypertonic saline
| Intervention | percentage of predicted (Median) |
|---|---|
| Before Treatment | 43.5 |
| After Treatment | 47 |
Measures ease of airway clearance through a 1-5 likert scale: 1) Very easy, 2) Easy, 3) Neither easy nor difficult, 4) Not easy, 5) Not at all easy. (NCT03623698)
Timeframe: Change from baseline (before treatment) and 12 months after treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Before Treatment | 4.21 |
| After Treatment | 2.13 |
"Pictorial visual scale Facial Rating of perceived exertion Scale. Measures ease of airway clearance. Values range starting in 0 (Extremely easy) to 10 (Extremely hard), including 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. Numbers are also associated with facial expressions." (NCT03623698)
Timeframe: Change from baseline (before treatment) and 12 months after treatment
| Intervention | score on a scale (Mean) |
|---|---|
| Before Treatment | 6.45 |
| After Treatment | 2 |
Nocturnal Transcutaneous Carbon Dioxide in kPa (NCT03623698)
Timeframe: Change from baseline (before treatment) and 12 months after treatment
| Intervention | Kilopascal (kPa) (Mean) |
|---|---|
| Before Treatment | 5.77 |
| After Treatment | 6.00 |
Treatments due to respiratory exacerbations (NCT03623698)
Timeframe: Change from baseline (before treatment) and 12 months after treatment
| Intervention | Courses of antibiotics (Median) | ||
|---|---|---|---|
| Total courses of antibiotics | Courses of Oral antibiotics | Courses of intravenous antibiotics | |
| After Treatment | 1 | 1.00 | 0.00 |
| Before Treatment | 4 | 2.50 | 1.00 |
"Hypertonic saline treatment questionnaire for legal guardian. Measures the perception of overall usefulness of nebulised hypertonic saline through a likert scale: Very useful, useful, neither useful or not useful, not useful, not at all useful." (NCT03623698)
Timeframe: At 12 months after starting treatment with hypertonic saline
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Very useful | useful | neither useful or not useful | not useful | not at all useful | |
| Parent's or Legal Guardians | 15 | 9 | 0 | 0 | 0 |
"Questionnaire: Hypertonic saline treatment questionnaire. Perception of overall usefulness of nebulised hypertonic saline: Useful, Not useful, I don't know." (NCT03623698)
Timeframe: At 12 months after starting treatment with hypertonic saline
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Useful | Not useful | I don't know | |
| Children and Young People With Neuromuscular Disease | 11 | 0 | 0 |
"Average radio tracer clearance through 90 minutes (MCC90) is primary index of mucociliary clearance at each study.~Primary study outcome: is absolute change in MCC90 between baseline and at end of treatment (where MCC measured 8-12 hours after final dose of study drug) - reflects sustained impact on MCC" (NCT01031706)
Timeframe: Baseline versus after completion of 4 week treatment period
| Intervention | percent clearance (Mean) |
|---|---|
| Hypertonic Saline | 2.77 |
| Placebo | -2.35 |
Absolute change in % predicted FEV1 between baseline and after 4 weeks of treatment calculated (NCT01031706)
Timeframe: Baseline and after 4 weeks of treatment
| Intervention | Percentage of predicted FEV1 (Mean) |
|---|---|
| Hypertonic Saline | 3.38 |
| Placebo | 1.09 |
"using chest x ray score. The score measures the amount of lung collapse (atelectasis) observed on a chest x-ray. For each of the 5 lung lobes, 1 point is given for linear atelectasis, 2 points for sub-segmental atelectasis and 3 points for lobar atelectasis. The range is 0-15 points, with higher scores reflecting more severe lung collapse." (NCT01945944)
Timeframe: during mechanical ventilation (typically 4 days - 2 weeks)
| Intervention | units on a scale (Median) |
|---|---|
| Placebo | 4.67 |
| Hypertonic Saline | 4 |
The baseline sodium was the last level measured prior to study initiation, typically within 24hrs of study initiation. The change in blood sodium level was calculated as the difference between the mean post-enrollment sodium level during ICU care and the sodium level at enrollment. (NCT01945944)
Timeframe: during hospitalization (typically 4 days - 2 weeks)
| Intervention | mEq/L (Median) |
|---|---|
| Placebo | 1 |
| Hypertonic Saline | -1.5 |
in % of tidal volume, using parameters on mechanical ventilator. Dead space is a measure of how much of the lung is not able to move air into and out of the body. Higher levels of dead space reflect higher levels of lung dysfunction. (NCT01945944)
Timeframe: during mechanical ventilation (typically 4 days - 2 weeks)
| Intervention | percentage of lung volume (Median) |
|---|---|
| Placebo | 29 |
| Hypertonic Saline | 37 |
(NCT01945944)
Timeframe: typically 4 days - 2 weeks
| Intervention | hours (Median) |
|---|---|
| Placebo | 129.5 |
| Hypertonic Saline | 208.1 |
measured in ml/cm H20/kg using parameters on mechanical ventilator (NCT01945944)
Timeframe: during mechanical ventilation (typically 4 days - 2 weeks)
| Intervention | mL/kg/cm-H20 (Median) |
|---|---|
| Placebo | 6.52 |
| Hypertonic Saline | 4.47 |
(NCT01945944)
Timeframe: during hospitalization (typically 4 days - 2 weeks)
| Intervention | days (Median) |
|---|---|
| Placebo | 15 |
| Hypertonic Saline | 17 |
(NCT01945944)
Timeframe: during hospitalization (typically 4 days - 2 weeks)
| Intervention | days (Median) |
|---|---|
| Placebo | 8 |
| Hypertonic Saline | 12 |
SaO2/FiO2. This is a measure of how will the lungs are providing oxygen to the body. Higher ratios reflect better lung function. (NCT01945944)
Timeframe: during mechanical ventilation (typically 4 days - 2 weeks)
| Intervention | ratio (Median) |
|---|---|
| Placebo | 239 |
| Hypertonic Saline | 188 |
as dichotomous outcome (yes/no) following drug administration (NCT01945944)
Timeframe: during mechanical ventilation (typically 4 days - 2 weeks)
| Intervention | percentage of drug doses w/ wheezing (Number) |
|---|---|
| Placebo | 3 |
| Hypertonic Saline | 1 |
Duration of action of hypertonic saline as determined by measurements of mucociliary clearance/cough clearance 4 hours post dose. (NCT01094704)
Timeframe: 1-4 hours post-dose
| Intervention | Absolute % change (Mean) |
|---|---|
| Hypertonic Saline - 1 Hour | 5.9 |
| Hypertonic Saline - 4 Hours | 6.7 |
"Self-reported symptom severity, used as a daily patient diary. The BCSS is a 12 point self-reported symptom severity score, consisting of 3 sections concerning how much difficulty the subject is having with breathing; subjective cough symptoms and trouble caused by sputum, each scoring between 0-4, combining to a total score of 0-12 (higher=worse). This scale is validated for daily use in Chronic Obstructive Pulmonary Disease (COPD)(21).~An exacerbation was defined as an increase in BCSS>1 with ≥5 days preceding stability." (NCT01952470)
Timeframe: Daily up to 3 months.
| Intervention | Exacerbations (Mean) | |
|---|---|---|
| Intervention phase | Follow-up phase | |
| Dornase Alfa | 0.94 | 2.64 |
| Isotonic Saline | 1.07 | 3.62 |
Sputum colour chart. Sputum colour has been shown to correlate with physiological infection in other chronic lung disease groups(22). (NCT01952470)
Timeframe: Daily up to 3 months.
| Intervention | days (Median) | |
|---|---|---|
| Intervention phase | Follow-up phase | |
| Dornase Alfa | 11.50 | 4.50 |
| Isotonic Saline | 8.50 | 6.00 |
An inflammatory marker measured with routine blood tests on admission with LRTI. Taken during inpatient (IP) stay and routinely on outpatient (OP) follow-up. Existing / available data only will be used - no extra routine bloods will be taken on account of study inclusion. (NCT01952470)
Timeframe: 1 month, 3 months.
| Intervention | mg/L (change) (Median) | |
|---|---|---|
| 1 month | 3 months | |
| Dornase Alfa | 1.00 | 12 |
| Isotonic Saline | 2.50 | 1.00 |
FER represents the proportion of a person's vital capacity that they are able to expire in the first second of forced expiration (FEV1) to the full, forced vital capacity (FVC). (NCT01952470)
Timeframe: 1 month, 3 months
| Intervention | Ratio (Mean) | |
|---|---|---|
| 1 month | 3 months | |
| Dornase Alfa | 66.33 | 62.79 |
| Isotonic Saline | 70.87 | 70.27 |
FEV1 is the maximal amount of air you can forcefully exhale in one second. (NCT01952470)
Timeframe: 1 month, 3 months.
| Intervention | Liters (L) - change (Mean) | |
|---|---|---|
| FEV1 L 1 month | FEV1 L 3 months | |
| Dornase Alfa | 2.11 | 1.91 |
| Isotonic Saline | 1.76 | 1.78 |
FEV1 is the maximal amount of air you can forcefully exhale in one second. (NCT01952470)
Timeframe: 1 month, 3 months
| Intervention | Percent (%) (Mean) | |
|---|---|---|
| 1 month | 3 months | |
| Dornase Alfa | 69.33 | 63.00 |
| Isotonic Saline | 58.33 | 57.60 |
Forced vital Capacity (FVC) is a measure of the amount of air someone can forcibly expel out of the lungs after taking a breath to fill the lungs as much as possible. (NCT01952470)
Timeframe: 1 month, 3 months
| Intervention | Liters (L) (Mean) | |
|---|---|---|
| 1 month | 3 months | |
| Dornase Alfa | 3.21 | 2.96 |
| Isotonic Saline | 2.46 | 2.50 |
Forced vital Capacity (FVC) is a measure of the amount of air someone can forcibly expel out of the lungs after taking a breath to fill the lungs as much as possible. (NCT01952470)
Timeframe: 1 month, 3 months
| Intervention | Percent (%) (Mean) | |
|---|---|---|
| 1 month | 3 months | |
| Dornase Alfa | 79.40 | 74.41 |
| Isotonic Saline | 62.07 | 63.73 |
Volume of air remaining in the lungs after normal expiration. (NCT01952470)
Timeframe: 1 month, 3 months
| Intervention | Liters (L) (Mean) | |
|---|---|---|
| 1 month | 3 months | |
| Dornase Alfa | 2.03 | 2.22 |
| Isotonic Saline | 1.80 | 1.78 |
Number of days spent in the acute inpatient setting. (NCT01952470)
Timeframe: Across study period (3 months).
| Intervention | Days (Mean) | |||
|---|---|---|---|---|
| All cause - intervention | All cause - follow-up | Respiratory - intervention | Respiratory - follow-up | |
| Dornase Alfa | 8.67 | 8.09 | 9.20 | 9.83 |
| Isotonic Saline | 12.50 | 11.38 | 21.50 | 14.33 |
Cough specific quality of life questionnaire. The LCQ is a 19-question tool, validated in chronic lung disease other than lung transplant(19). Scale 1-7 for physical, psychological, social. Combined score of 3-21 for total. Lower=worse. (NCT01952470)
Timeframe: 1 month, 3 months.
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Physical 1 month | Physical 3 months | Psychological 1 month | Psychological 3 months | Social 1 month | Social 3 months | Total 1 month | Total 3 months | |
| Dornase Alfa | 5.73 | 5.56 | 6.32 | 6.03 | 6.33 | 6.12 | 17.26 | 17.70 |
| Isotonic Saline | 5.12 | 5.69 | 5.87 | 6.05 | 5.75 | 6.07 | 16.72 | 17.81 |
"A measure of ventilation inhomogeneity as measured during multiple breath washout (MBW) of inert tracer gases. It has been shown that this test is a potentially more sensitive measure of peripheral airway obstruction than regular spirometry in short term (4 week) mucolytic interventional studies in pediatric Cystic Fibrosis (CF)(17-18). This test would be performed within the respiratory physiology lung function laboratory on site at all assessment points, by an assessor who is blinded to group allocation for follow up data collection.~Conventionally used primary endpoints in this population, such as regular spirometry(3), may be unable to detect between group differences without large sample sizes and long treatment durations. Based on current evidence from non-lung transplant populations, LCI has been able to show short-term change, whereas regular spirometry has not shown change(17-18)." (NCT01952470)
Timeframe: 1 month, 3 months
| Intervention | Index (change) (Mean) | |
|---|---|---|
| 1 month | 3 months | |
| Dornase Alfa | 10.68 | 10.09 |
| Isotonic Saline | 11.65 | 11.19 |
"Multiple breath washout is a sensitive measure of respiratory function performed with the subject in a seated position, breathing a fixed tidal volume (1L) of inert gas (nitrogen) from functional residual capacity (FRC) via mouthpiece.~Two common outcomes of MBW are Sacin, a measure of gas mixing at the diffusion front, or acinar entrance in the airways, and Scond, in the proximal, conductive zones. An increase in either Sacin or Scond represents an increase in ventilation heterogeneity (deterioration). Both increase with age, normal values are non-zero between 0-0.25(Sacin) and 0-0.1(Scond)." (NCT01952470)
Timeframe: 1 month, 3 months
| Intervention | Gas mixing index (Sacin / Scond) (Mean) | |||
|---|---|---|---|---|
| Sacin 1 month | Sacin 3 months | Scond 1 month | Scond 3 months | |
| Dornase Alfa | 0.348 | 0.354 | 0.045 | 0.033 |
| Isotonic Saline | 0.383 | 0.356 | 0.026 | 0.021 |
Number of admissions to the acute setting. (NCT01952470)
Timeframe: Over study period (3 months).
| Intervention | Hospitalizations (Number) | |||
|---|---|---|---|---|
| All cause - intervention | All cause - follow-up | Respiratory - intervention | Respiratory - follow-up | |
| Dornase Alfa | 8 | 12 | 7 | 6 |
| Isotonic Saline | 4 | 8 | 2 | 6 |
Antibiotic use for the treatment of lower respiratory tract infections (LRTI) only. (NCT01952470)
Timeframe: Over study period (3 months).
| Intervention | Days (Median) | |
|---|---|---|
| Intervention phase | Follow-up phase | |
| Dornase Alfa | 23.50 | 14.00 |
| Isotonic Saline | 25.00 | 10.50 |
"The SGRQ is a 2-part questionnaire, validated in chronic lung disease other than lung transplant(20).~50 items, 76 weighted responses. Scores range 0-100, higher=worse." (NCT01952470)
Timeframe: 1 month, 3 months.
| Intervention | units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Symptom 1 month | Symptom 3 months | Activity 1 month | Activity 3 months | Impact 1 month | Impact 3 months | Total 1 month | Total 3 months | |
| Dornase Alfa | 55.65 | 48.52 | 40.82 | 53.18 | 20.59 | 25.96 | 32.50 | 37.97 |
| Isotonic Saline | 61.93 | 51.47 | 57.38 | 53.81 | 30.72 | 33.90 | 43.58 | 40.81 |
Pre-treatment spirometry measurement assessed at the time of study enrollment. Post-treatment spirometry measurement assessed following the administration of one time 5mg nebulized albuterol sulfate treatment. Assessments taken at baseline (prior to albuterol therapy) and 10 min post-treatment. Change in FEV1 calculated as post-treatment FEV1 minus pre-treatment FEV1 (NCT02566902)
Timeframe: 10 minutes
| Intervention | %predicted (Mean) |
|---|---|
| T-piece Nebulizer | 13.8 |
| Breath-Enhanced Nebulizer | 9.1 |
"Blinded research personnel will assess subject's heart rate by auscultation and/or pulse palpation prior to and immediately following albuterol administration.~Pre-treatment assessment at the time of study enrollment. Post-treatment assessment following the administration of one time 5mg nebulized albuterol sulfate treatment. Assessments taken at baseline (prior to albuterol therapy) and 10 min post-treatment. Change in heart rate calculated as post-treatment heart rate minus pre-treatment heart rate." (NCT02566902)
Timeframe: 10 minutes
| Intervention | beats per minute (Mean) |
|---|---|
| T-piece Nebulizer | 4.34 |
| Breath-Enhanced Nebulizer | 15.05 |
"Based on examination and auscultation of lungs prior to and immediately following albuterol administration.~PAS score is on a scale of 0-10 which is a sum of five separate sub-scores each on a scale of 0-2. The five sub-scores are:~Respiratory rate (6-12yr/>12yr): <=26/23 (0), 27-30/24-27 (1), >31/28 (2)~Oxygenation: >95% (0), 90-95 (1), <90 (2)~Auscultation: clear/end expiratory wheeze (0), expiratory wheeze (1), biphasic wheeze/diminished (2)~Work of Breathing (accessory muscles): <= 1 (0), 2 (1), >=3 (2)~Dyspnea: Full sentences (0), Partial sentences (1), Single words (2)~Pre-treatment assessment at the time of study enrollment. Post-treatment assessment following the administration of one time 5mg nebulized albuterol sulfate treatment. Assessments taken at baseline (prior to albuterol therapy) and 10 min post-treatment. Change in PAS calculated as post-treatment PAS minus pre-treatment PAS." (NCT02566902)
Timeframe: 10 minutes
| Intervention | score on a scale (Median) |
|---|---|
| T-piece Nebulizer | -1 |
| Breath-Enhanced Nebulizer | -2 |
"Determined by examination and auscultation of lungs to prior to and immediately following albuterol administration.~PASS is a total score on a scale of 0-6 which is calculated as a sum of three sub-scores, each on a scale of 0-2. The sub-scores are:~Wheezing: None or Mild (0), Moderate (1), Severe wheezing or absent wheezing due to poor air exchange (2)~Work of breathing (accessory muscle use or retractions): None or mild (0), Moderate (1), Severe (2)~Prolonged expiration: Normal or mildly prolonged (0), moderately prolonged (1), severely prolonged (2)~Pre-treatment assessment at the time of study enrollment. Post-treatment assessment following the administration of one time 5mg nebulized albuterol sulfate treatment. Assessments taken at baseline (prior to albuterol therapy) and 10 min post-treatment. Change in PASS calculated as post-treatment PASS minus pre-treatment PASS." (NCT02566902)
Timeframe: 10 minutes
| Intervention | score on a scale (Median) |
|---|---|
| T-piece Nebulizer | -1 |
| Breath-Enhanced Nebulizer | -1 |
"Respiratory rate will be measured by observation and auscultation over 30 seconds prior to and immediately following albuterol administration~Pre-treatment assessment at the time of study enrollment. Post-treatment assessment following the administration of one time 5mg nebulized albuterol sulfate treatment. Assessments taken at baseline (prior to albuterol therapy) and 10 min post-treatment. Change in respiratory rate calculated as post-treatment respiratory rate minus pre-treatment respiratory rate." (NCT02566902)
Timeframe: 10 minutes
| Intervention | breaths/min (Mean) |
|---|---|
| T-piece Nebulizer | -3.1 |
| Breath-Enhanced Nebulizer | -3.2 |
Total length of stay will be assessed at the time of Emergency Department disposition which will be approximately 3 hours, but will be assessed up to 24 hours depending on duration of ED stay. (NCT02566902)
Timeframe: Up to 24 hours
| Intervention | minutes (Mean) |
|---|---|
| T-piece Nebulizer | 246.3 |
| Breath-Enhanced Nebulizer | 246.2 |
"Subjects and parents/guardians will be asked whether subjects experienced nausea, vomiting, palpitations, headache, dizziness either during (assessed by non-blinded personnel) or following treatment (assessed by blinded personnel during post-treatment assessment). Subject and parent/guardian will also be asked if any other side effects were experienced." (NCT02566902)
Timeframe: 10 minutes
| Intervention | Participants (Count of Participants) |
|---|---|
| T-piece Nebulizer | 5 |
| Breath-Enhanced Nebulizer | 5 |
Admission rate to inpatient hospital will be assessed at the time of Emergency Department disposition which will be approximately 3 hours, but will be assessed up to 24 hours depending on duration of ED stay. (NCT02566902)
Timeframe: Up to 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| T-piece Nebulizer | 11 |
| Breath-Enhanced Nebulizer | 11 |
Cumulative dose of albuterol in mg will be assessed at the time of Emergency Department disposition which will be approximately 3 hours, but will be assessed up to 24 hours depending on duration of ED stay. (NCT02566902)
Timeframe: up to 24 hours
| Intervention | mg (Mean) |
|---|---|
| T-piece Nebulizer | 18.2 |
| Breath-Enhanced Nebulizer | 18.7 |
6 reviews available for albuterol and Cystic Fibrosis
| Article | Year |
|---|---|
Nebuliser systems for drug delivery in cystic fibrosis.
Topics: Aerosols; Albuterol; Anti-Bacterial Agents; Bronchodilator Agents; Carbenicillin; Colistin; Cromolyn | 2013 |
WITHDRAWN: Inhaled bronchodilators for cystic fibrosis.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Bronchial Hyperreactivity; Bronchodilator Agents; Child; | 2016 |
Inhaled bronchodilators for cystic fibrosis.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Bronchial Hyperreactivity; Bronchodilator Agents; Child; | 2005 |
Inhalation solutions: which one are allowed to be mixed? Physico-chemical compatibility of drug solutions in nebulizers.
Topics: Acetylcysteine; Administration, Inhalation; Albuterol; Anti-Asthmatic Agents; Anti-Bacterial Agents; | 2006 |
Bronchodilators in cystic fibrosis.
Topics: Adolescent; Adult; Albuterol; Bronchodilator Agents; Child, Preschool; Chronic Disease; Clinical Tri | 2000 |
Immediate effect of various treatments on lung function in infants with cystic fibrosis.
Topics: Acetylcysteine; Administration, Inhalation; Albuterol; Combined Modality Therapy; Cystic Fibrosis; H | 1989 |
32 trials available for albuterol and Cystic Fibrosis
| Article | Year |
|---|---|
Effects of inhaled hypertonic (7%) saline on lung function test in preschool children with cystic fibrosis: results of a crossover, randomized clinical trial.
Topics: Administration, Inhalation; Albuterol; Anti-Asthmatic Agents; Child, Preschool; Cross-Over Studies; | 2017 |
Induced sputum compared to bronchoalveolar lavage in young, non-expectorating cystic fibrosis children.
Topics: Albuterol; Bronchoalveolar Lavage; Bronchoalveolar Lavage Fluid; Bronchodilator Agents; Child; Child | 2014 |
Effects of exercise intensity compared to albuterol in individuals with cystic fibrosis.
Topics: Adolescent; Adult; Albuterol; Blood Gas Analysis; Breathing Exercises; Bronchodilator Agents; Cross- | 2015 |
Moderate intensity exercise mediates comparable increases in exhaled chloride as albuterol in individuals with cystic fibrosis.
Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Chlorides; Cross-Over Studies; Cy | 2015 |
β2-Adrenergic receptor agonists activate CFTR in intestinal organoids and subjects with cystic fibrosis.
Topics: Administration, Oral; Adrenergic beta-2 Receptor Agonists; Albuterol; Biological Assay; Bronchi; Cel | 2016 |
Safety and tolerability of inhaled hypertonic saline in young children with cystic fibrosis.
Topics: Administration, Inhalation; Albuterol; Bronchodilator Agents; Child; Child, Preschool; Cystic Fibros | 2008 |
Effects of salmeterol on arterial oxyhemoglobin saturations in patients with cystic fibrosis.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Cystic Fibrosis; Female; Hum | 2002 |
Effectiveness and tolerability of high-dose salmeterol in cystic fibrosis.
Topics: Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Blood Pressure; Bronchodilator Agents; Cross-Ov | 2002 |
Pulmonary function and sputum production in patients with cystic fibrosis: a pilot study comparing the PercussiveTech HF device and standard chest physiotherapy.
Topics: Adolescent; Adult; Aerosols; Albuterol; Bronchodilator Agents; Child; Cross-Over Studies; Cystic Fib | 2004 |
Effect of nebulized albuterol on blood glucose in patients with diabetes mellitus with and without cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Blood Glucose; Bronchodilator Agents; Cyst | 2005 |
Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Cross-Over Studies; Cystic F | 2005 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch | 2006 |
Effect of albuterol on maximal exercise capacity in cystic fibrosis.
Topics: Administration, Inhalation; Adult; Albuterol; Bronchodilator Agents; Cross-Over Studies; Cystic Fibr | 2007 |
Response to aerosol salbutamol, SCH 1000, and placebo in cystic fibrosis.
Topics: Adolescent; Adult; Aerosols; Albuterol; Atropine Derivatives; Child; Clinical Trials as Topic; Cysti | 1980 |
Comparison of effects of an intrapulmonary percussive ventilator to standard aerosol and chest physiotherapy in treatment of cystic fibrosis.
Topics: Adolescent; Adult; Aerosols; Albuterol; Bronchodilator Agents; Child; Cromolyn Sodium; Cystic Fibros | 1995 |
Effect of oral digoxin, topical ouabain and salbutamol on transepithelial nasal potential difference in patients with cystic fibrosis.
Topics: Adolescent; Adult; Albuterol; Amiloride; Cystic Fibrosis; Digoxin; Double-Blind Method; Enzyme Inhib | 1995 |
[Role of anticholinergic agents in the treatment of cystic fibrosis].
Topics: Albuterol; Bronchial Hyperreactivity; Child; Cystic Fibrosis; Drug Combinations; Forced Expiratory V | 1995 |
Comparison of intrapulmonary percussive ventilation and chest physiotherapy. A pilot study in patients with cystic fibrosis.
Topics: Adolescent; Adult; Albuterol; Child; Cystic Fibrosis; Drainage, Postural; Female; Humans; Male; Muco | 1994 |
Comparison of efficacy of salbutamol and sodium cromoglycate in the prevention of ticarcillin-induced bronchoconstriction.
Topics: Adolescent; Albuterol; Bronchoconstriction; Child; Cromolyn Sodium; Cystic Fibrosis; Double-Blind Me | 1993 |
The effect of high doses of inhaled salbutamol and ipratropium bromide in patients with stable cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Adult; Airway Resistance; Albuterol; Child; Cystic Fibrosis; | 1993 |
Plasma concentrations and effects of salbutamol administered orally to patients with cystic fibrosis.
Topics: Administration, Oral; Adrenergic beta-Agonists; Adult; Albuterol; Bronchodilator Agents; Cystic Fibr | 1995 |
Short-term and long-term effects of albuterol aerosol therapy in cystic fibrosis: a preliminary report.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchi; | 1995 |
The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis.
Topics: Adolescent; Adult; Albuterol; Bronchodilator Agents; Cross-Over Studies; Cystic Fibrosis; Double-Bli | 1996 |
Short-term effects of regular salmeterol treatment on adult cystic fibrosis patients.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Cross-Over Studies; Cystic F | 1997 |
Comparison of drug delivery from conventional versus "Venturi" nebulizers.
Topics: Administration, Inhalation; Adolescent; Aerosols; Age Factors; Albuterol; Bronchodilator Agents; Chi | 1997 |
A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Albuterol; Bronchodilator Agents; Child; Child, Preschool; C | 1998 |
Effects of standard and high doses of salmeterol on lung function of hospitalized patients with cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Cross-Over Studi | 1999 |
Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Adult; Aerosols; Airway Obstruction; Albuterol; Bronchodilat | 2001 |
Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis.
Topics: Adolescent; Adult; Albuterol; Bronchi; Child; Cystic Fibrosis; Double-Blind Method; Drug Therapy, Co | 1992 |
Efficacy of salbutamol and ipratropium bromide in decreasing bronchial hyperreactivity in children with cystic fibrosis.
Topics: Adolescent; Albuterol; Bronchial Hyperreactivity; Bronchial Provocation Tests; Child; Cystic Fibrosi | 1992 |
A controlled trial of long-term bronchodilator therapy in cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Albuterol; Bronchial Provocation Tests; Cystic Fibrosis; Dou | 1991 |
Immediate effect of various treatments on lung function in infants with cystic fibrosis.
Topics: Acetylcysteine; Administration, Inhalation; Albuterol; Combined Modality Therapy; Cystic Fibrosis; H | 1989 |
42 other studies available for albuterol and Cystic Fibrosis
| Article | Year |
|---|---|
Topics: Administration, Inhalation; Albuterol; Cystic Fibrosis; Epithelial Cells; Healthy Volunteers; Humans | 2023 |
Subacute TGFβ Exposure Drives Airway Hyperresponsiveness in Cystic Fibrosis Mice through the PI3K Pathway.
Topics: Adrenergic beta-Agonists; Albuterol; Animals; Bronchoconstriction; Cystic Fibrosis; Goblet Cells; Hy | 2020 |
Crossover Evaluation of Compressors and Nebulizers Typically Used by Cystic Fibrosis Patients.
Topics: Administration, Inhalation; Aerosols; Albuterol; Bronchodilator Agents; Cross-Over Studies; Cystic F | 2018 |
Chronic β2AR stimulation limits CFTR activation in human airway epithelia.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Aminophenols; Aminopyridines; Benzodioxoles; Cell Li | 2018 |
In vitro evaluation of positive expiratory pressure devices attached to nebulizers.
Topics: Adult; Albuterol; Bronchodilator Agents; Child; Cystic Fibrosis; Equipment Design; Humans; In Vitro | 2014 |
Longitudinal evaluation of compressor/nebulizer performance.
Topics: Administration, Inhalation; Aerosols; Albuterol; Bronchodilator Agents; Cystic Fibrosis; Equipment D | 2014 |
Stimulation of β2-adrenergic receptor increases CFTR function and decreases ATP levels in murine hematopoietic stem/progenitor cells.
Topics: Adenosine Triphosphate; Albuterol; Analysis of Variance; Animals; Biomarkers; Cells, Cultured; Chlor | 2015 |
Impaired cardiac and peripheral hemodynamic responses to inhaled β₂-agonist in cystic fibrosis.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Cardiac Output; C | 2015 |
SINUSITIS, BRONCHIECTASIS, AND FLATUS IN A SUMATRAN ORANGUTAN (PONGO ABELII): COULD THIS BE CYSTIC FIBROSIS?
Topics: Albuterol; Animals; Anti-Bacterial Agents; Ape Diseases; Bronchiectasis; Bronchodilator Agents; Cyst | 2016 |
Treatment with rhDNase in patients with cystic fibrosis alters in-vitro CHIT-1 activity of isolated leucocytes.
Topics: Adolescent; Adult; Aged; Albuterol; Aspergillus fumigatus; Azithromycin; Bacteria; Cystic Fibrosis; | 2016 |
Salmeterol restores secretory functions in cystic fibrosis airway submucosal gland serous cells.
Topics: Albuterol; Cell Line; Cell Polarity; Chlorides; Colforsin; Cyclic AMP; Cystic Fibrosis; Cystic Fibro | 2009 |
Pulmonary deposition of inhaled tobramycin prior to and after respiratory therapy and use of inhaled albuterol in cystic fibrosis patients colonized with Pseudomonas aeruginosa.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronchodilator Agen | 2009 |
Search and rescue: finding ways to correct deltaF508 CFTR.
Topics: Albuterol; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Ion Channel | 2009 |
β1, β2, and β3 adrenoceptors and Na+/H+ exchanger regulatory factor 1 expression in human bronchi and their modifications in cystic fibrosis.
Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Benzoates; Bronchi; Case-Control Studies; Cell Lin | 2011 |
Inhaled colistin for the treatment of tracheobronchitis and pneumonia in critically ill children without cystic fibrosis.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Administration, Inhalation; Albuterol; Anti-Bacte | 2010 |
Nebulized hypertonic saline via positive expiratory pressure versus via jet nebulizer in patients with severe cystic fibrosis.
Topics: Administration, Inhalation; Adult; Albuterol; Anti-Bacterial Agents; Bronchodilator Agents; Cystic F | 2011 |
Hypertonic saline and PEP: is it worth a try?
Topics: Administration, Inhalation; Albuterol; Anti-Bacterial Agents; Bronchodilator Agents; Cystic Fibrosis | 2011 |
Influence of genetic variation of the β2-adrenergic receptor on lung diffusion in patients with cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Carbo | 2011 |
Hyperpolarized HHe 3 MRI of the lung in cystic fibrosis: assessment at baseline and after bronchodilator and airway clearance treatment.
Topics: Administration, Inhalation; Adult; Albuterol; Bronchodilator Agents; Cystic Fibrosis; Deoxyribonucle | 2005 |
The interrupter technique to assess airway responsiveness in children with cystic fibrosis.
Topics: Adolescent; Airway Resistance; Albuterol; Bronchodilator Agents; Child; Cystic Fibrosis; Female; Hum | 2007 |
Calculating expected lung deposition of aerosolized administration of AAV vector in human clinical studies.
Topics: Administration, Inhalation; Aerosols; Albuterol; Cystic Fibrosis; Dependovirus; Genetic Therapy; Gen | 2007 |
Iontophoretic beta-adrenergic stimulation of human sweat glands: possible assay for cystic fibrosis transmembrane conductance regulator activity in vivo.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Albuterol; Aminophylline; Calcium; Cells, Cul | 2008 |
Lung function in cystic fibrosis: acute effect of salbutamol.
Topics: Adolescent; Albuterol; Child; Cystic Fibrosis; Female; Forced Expiratory Volume; Humans; Lung; Lung | 1980 |
Reversible airway obstruction in cystic fibrosis.
Topics: Adolescent; Age Factors; Airway Obstruction; Albuterol; Asthma; Child; Child, Preschool; Cystic Fibr | 1980 |
Effect of salbutamol on gas compression in cystic fibrosis and asthma.
Topics: Adolescent; Albuterol; Asthma; Bias; Child; Cystic Fibrosis; Female; Forced Expiratory Volume; Human | 1994 |
Increased physiological dead space during exercise after bronchodilation in cystic fibrosis.
Topics: Adolescent; Airway Resistance; Albuterol; Bronchi; Cystic Fibrosis; Female; Humans; Male; Physical E | 1993 |
Clinical value of monitoring eosinophil activity in asthma.
Topics: Albuterol; Asthma; Blood Proteins; Bronchodilator Agents; Budesonide; Child; Child, Preschool; Cysti | 1995 |
Activation of endogenous deltaF508 cystic fibrosis transmembrane conductance regulator by phosphodiesterase inhibition.
Topics: 1-Methyl-3-isobutylxanthine; Adrenergic beta-Agonists; Albuterol; Base Sequence; Calcium; Cell Line; | 1996 |
The choice of jet nebulizer, nebulizing flow, and addition of albuterol affects the output of tobramycin aerosols.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Aerosols; Albuterol; Anti-Bacterial Agents; Ca | 1997 |
No paradoxical bronchodilator response with forced oscillation technique in children with cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Airway Resistance; Albuterol; Bron | 1998 |
Inhalation therapy in cystic fibrosis.
Topics: Acetylcysteine; Albuterol; Anti-Bacterial Agents; Cystic Fibrosis; Humans; Penicillins; Respiratory | 1975 |
Response to inhaled bronchodilators and nonspecific airway hyperreactivity in children with cystic fibrosis.
Topics: Adolescent; Albuterol; Bronchial Provocation Tests; Bronchodilator Agents; Child; Cystic Fibrosis; F | 1992 |
Lung volumes measured by the forced rebreathing technique in children with airways obstruction.
Topics: Adolescent; Albuterol; Asthma; Child; Cystic Fibrosis; Female; Humans; Lung Volume Measurements; Mal | 1992 |
A new baby-spacer device for aerosolized bronchodilator administration in infants with bronchopulmonary disease.
Topics: Albuterol; Cystic Fibrosis; Humans; Infant; Infant, Newborn; Respiratory Distress Syndrome, Newborn; | 1992 |
Improvement from pulmonary hyperinflation and bronchial obstruction following sympathomimetics systemically given in infants with broncho-pulmonary diseases.
Topics: Airway Resistance; Albuterol; Bronchitis; Bronchopulmonary Dysplasia; Cystic Fibrosis; Humans; Hyali | 1990 |
Respiratory impedance and multibreath N2 washout in healthy, asthmatic, and cystic fibrosis subjects.
Topics: Adolescent; Adult; Airway Resistance; Albuterol; Asthma; Bronchi; Child; Cystic Fibrosis; Female; Fo | 1990 |
Early detection of lung function abnormalities in infants with cystic fibrosis.
Topics: Airway Resistance; Albuterol; Cystic Fibrosis; Humans; Infant; Infant, Newborn; Lung; Lung Diseases, | 1989 |
Dose-response relationships and time course of the response to systemic beta adrenoreceptor agonists in infants with bronchopulmonary disease.
Topics: Airway Resistance; Albuterol; Bronchitis; Cystic Fibrosis; Dose-Response Relationship, Drug; Humans; | 1988 |
Airway obstruction and airway wall instability in cystic fibrosis: the isolated and combined effect of theophylline and sympathomimetics.
Topics: Adolescent; Adult; Airway Obstruction; Albuterol; Child; Cystic Fibrosis; Drug Therapy, Combination; | 1988 |
Effect of salbutamol on resting energy expenditure in patients with cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Cystic Fibrosis; Energy Metabolism; Female | 1987 |
Pharmacokinetics of inhaled salbutamol in patients with cystic fibrosis versus healthy young adults.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Biological Availability; Cystic Fibrosis; | 1987 |
Can thoracic gas volume be measured in infants with airways obstruction?
Topics: Airway Obstruction; Airway Resistance; Albuterol; Bronchiolitis, Viral; Cystic Fibrosis; Functional | 1986 |